Skip to main content

Advertisement

SpringerLink
Log in

Caveat regarding CMS Merit-based Incentive Payment Systems incidental adrenal nodule measure

  • Perspective
  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Current Medicare MIP measures encourage radiologists not to recommend follow-up for ≤ 1 cm adrenal nodules. However, a radiologist may be the first to discover a small, subclinical pheochromocytoma. As such, recognition of the enhancement pattern of pheochromocytoma is important to ensure detection and properly guide management, which begins with clinical and laboratory assessment for elevated catecholamines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Measure #405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions– National Quality Strategy Domain: Effective Clinical Care https://qpp.cms.gov/docs/QPP_quality_measure_specifications/Claims-Registry-Measures/2017_Measure_405_Claims.pdf. Accessed 5 Aug 5 2018

  2. Mayo-Smith WW, Song JH, Boland GL, et al. (2017) Management of incidental adrenal masses: a white paper of the ACR incidental findings committee. J Am Coll Radiol. 14:1038–1044

    Article  PubMed  Google Scholar 

  3. Oshmyansky AR, Mahammedi A, Dackiw A, et al. (2013) Serendipity in the diagnosis of pheochromocytoma. J Comput Assist Tomogr. 37(5):820–823

    Article  PubMed  Google Scholar 

  4. Motta-Ramierz GA, Remer EM, Herts BR, Gill IS, Hamrahian AH (2005) Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. AJR 185:684

    Article  Google Scholar 

  5. Kopetschke R, Slisko M, Kilisli A, et al. (2009) Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 161(2):355–361

    Article  CAS  PubMed  Google Scholar 

  6. Goldstein RE, O’Neill JA, Holcomb GW, et al. (1999) Clinical experience over 48 years with pheochromocytoma. Ann Surg. 229:755

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Northcutt BG, Raman S, Long CM, et al. (2013) MDCT of adrenal masses: can dual-phase enhancement patterns be used to distinguish between adenoma and pheochromocytoma. AJR 201:834–839

    Article  PubMed  Google Scholar 

  8. Northcutt BG, Trakhtenbroit MA, Gomez EN, Fishman EK, Johnson PT (2016) Adrenal adenoma and pheochromocytoma: comparison of multidetector CT venous enhancement levels and washout characteristics. J Comput Assist Tomogr. 40:194–200

    Article  PubMed  Google Scholar 

  9. Stamm M, Abele JT (2014) Streamlining the imaging of clinically suspected pheochromocytoma: using urine metanephrines to decrease imaging costs. Can Assoc Radiol J. 65:372–378

    Article  PubMed  Google Scholar 

  10. Sawka AM, Jaeschke R, Singh RJ, Young WF Jr (2003) A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 88:553–558

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Johns Hopkins Hospital, 601 N. Caroline Street, Baltimore, MD, 21287, USA

    Joseph Holman, Elliot K. Fishman & Pamela T. Johnson

  2. Department of Endocrinology, Johns Hopkins Hospital, 600 N. Wolfe Street, Baltimore, MD, 21287, USA

    Roberto Salvatori

Authors
  1. Joseph Holman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roberto Salvatori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elliot K. Fishman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pamela T. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pamela T. Johnson.

Ethics declarations

Conflict of interest

Joseph Holman and Roberto Salvatori have nothing to disclosures. Elliot K. Fishman received grant funding from GE Healthcare and Siemens and Founder and stockholder of HipGraphics. Pamela T. Johnson is a Consultant to Oliver Wyman.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Holman, J., Salvatori, R., Fishman, E.K. et al. Caveat regarding CMS Merit-based Incentive Payment Systems incidental adrenal nodule measure. Abdom Radiol 44, 1152–1154 (2019). https://doi.org/10.1007/s00261-018-1834-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-018-1834-3

Keywords

Search

Navigation